HF10 Therapy for the Treatment of Chronic, Focal, Neuropathic Pain Following Orthopedic Surgical Intervention of the Knee(s) - A Multicenter, Prospective Clinical Trial

Nevro Corp1 site in 1 country3 target enrollmentMarch 14, 2019

ConditionsChronic Pain Post-Procedural

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Chronic Pain Post-Procedural
Sponsor: Nevro Corp
Enrollment: 3
Locations: 1
Primary Endpoint: Responders and Improvement in Oxford Knee Score (OKS)
Status: Terminated
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This is a multi-center study where patients who meet the eligibility criteria will be treated with HF10 therapy for their chronic knee pain post-orthopedic surgery. The primary endpoint will be assessed at 3 months, but observational assessments will continue until study completion at 12 months following implant.

Registry

clinicaltrials.gov

Start Date

March 14, 2019

End Date

December 12, 2019

Last Updated

5 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Nevro Corp

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Have been diagnosed with chronic, focal, neuropathic pain following orthopedic surgery(ies) of the knee(s).
•Average pain intensity (over a period of 7 days) of ≥5 out 10 cm on the Visual Analog Scale (VAS) in the primary area of pain at enrollment.
•Have a score of at least 4 out of 10 in Douleur Neuropathique 4 (DN4) questionnaire at the time of enrollment or eligibility verification.
•Deemed not to have surgical loosening or other complications from the surgery that affect the stability of the knee.
•Have stable neurological status measured by motor, sensory and reflex function as determined by the investigator.
•Be on stable pain medications, as determined by the Investigator, for at least 28 days prior to assessing pain intensity as described in inclusion criterion #2, and be willing to stay on those medications with no dose adjustments until activation of the permanently implanted SCS device.

Exclusion Criteria

•Have radiculopathy or radicular leg pain resulting from failed back surgery.
•Have a medical condition or pain in other area(s), not intended to be treated with SCS, that could interfere with study procedures, accurate pain reporting, and/or confound evaluation of study endpoints, as determined by the Investigator (such as primary headache diagnosis or fibromyalgia).
•Have a current diagnosis of a progressive neurological disease such as multiple sclerosis (MS), chronic inflammatory demyelinating polyneuropathy, rapidly progressive arachnoiditis, brain or spinal cord tumor, central deafferentation syndrome, acute herniating disc, severe spinal stenosis and brachial plexus avulsion as determined by the Investigator.
•Have a current diagnosis or condition such as a coagulation disorder, bleeding diathesis, platelet dysfunction, progressive peripheral vascular disease or uncontrolled diabetes mellitus that presents excess risk for performing the procedure as determined clinically by the Investigator.
•Have any prior experience with SCS.
•Have objective evidence of epidural scarring and/or any signs or symptoms of myelopathy as determined by the investigator.
•Be benefitting from an interventional procedure to treat their trunk or limb pain (Subjects should be enrolled at least 30 days from last benefit).
•Have an existing drug pump and/or another active implantable device such as a pacemaker.
•Be involved in an injury claim under current litigation.
•Have an active or unsettled worker's compensation claim.

Outcomes

Primary Outcomes

Responders and Improvement in Oxford Knee Score (OKS)

Time Frame: 3 months

The OKS is a patient self-completion patient reported outcome containing 12 questions on activities of daily living with a recall period of 4 weeks. The OKS has been developed and validated specifically to assess function and pain after total knee replacement. The higher the score indicates improvement. The proportion of implanted subjects who are responders (achieved ≥ 50% pain relief) to HF10 therapy for treatment of their chronic, post-surgical knee pain or reporting at least a 4-point improvement in their Oxford Knee Score (OKS).

Secondary Outcomes

Change in Disability and Functioning(3, 6, and 12 months)
Change in Functioning(3 and 12 months)
Change in pain relief as measured by the Visual Analog Scale (VAS)(3 and 12 months)
Change from baseline in pain experience: Short-Form McGill Pain Questionnaire (SF-MPQ-2) scores(3 and 12 months)
Safety profile: Incidence of AEs over time(3, 6 and 12 months)
Global Impression of Change(3 and 12 months)
Change in Quality of Life as measured by the EuroQol five-dimensional questionnaire (EQ-5D-5L)(3 and 12 months)
Change in Sleep as measured by the Pain and sleep Questionnaire (PSQ)(3 and 12 months)
Medication(3 and 12 months)
Safety profile: Neurological assessment over time by a physician and exam(3, 6 and 12 months)